Harvard i-lab | A OneTeam Collective Challenge: To Shape The Evolution of the NFL

The Alumni Launch Lab supports alumni innovators from all 13 Harvard schools, fostering a global ecosystem of entrepreneurs who are truly changing the world. Uploaded 18-07-25Learn more here: https://innovationlabs.harvard.edu/labs/alumni-launch-labVideography by Owen Mack www.cobrandit.com Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

In Part 4 of Michael Skok's Harvard i-lab lecture series, "Startup Secrets: An insiders guide to unfair competitive advantage," Skok describes the fundamentals of building a go-to-market strategy for your business.Uploaded 07-05-12You can read more about Michael Skok, and his Startup Secrets on his website: http://mjskok.com/ and follow him on twitter at http://twitter.com/mjskokLearn more about the Harvard Innovation Lab at http://i-lab.harvard.edu/ and follow us on Twitter at http://twitter.com/innovationlab and like us on facebook at https://www.facebook.com/harvardinnovationlab Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Note: There will NOT be a Longwood to ilab shuttle.Uploaded 02-12-14Information is a valuable asset to any life sciences or technology venture. This substantive session will help to frame data-related limitations, systems and practices that new companies are likely to encounter. The collection, analysis, storage and disclosure of information is often critical for developing and commercializing products, establishing strategic collaborations, securing regulatory approvals, and completing corporate acquisitions and other transactions.When information includes personally identifiable information, it is necessary to address special regulatory and contractual considerations in a company’s earliest stages. By pursuing data privacy and security “by design,” startup companies can be prepared for the privacy and security landscape and, hopefully, avoid burdensome “retrofitting” efforts that can disrupt future growth. You will learn:- how to navigate the increasingly complex regulatory framework governing personally identifiable information, including the regulation of health-related data- which key contractual issues affect your venture companies that handle such data through their license agreements, collaborations and sales contracts This presentation will be led by partners of the WilmerHale law firm to provide an overview of key regulatory and contractual considerations most likely to affect life sciences and technology startup companies. - Barry Hurewitz, Regulatory and Government Affairs practice- Jeff Johnson, Technology Transaction and Licensing practiceLearn more about the Harvard Innovation Lab at http://i-lab.harvard.edu/ and follow us on Twitter at http://twitter.com/innovationlab and like us on Facebook athttps://www.facebook.com/harvardinnovationlab Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

“Our world is more isolated and lonely than ever before. We need more remote work opportunities and a greater sense of connectedness and meaning. Naya strives to be a digital studio and ecosystem that can facilitate a sense of community, collaboration, and connection across the world at a time when we need it most.” - Saad Rajan and Vivek HV, of @naya__studioUploaded 22-04-20.To learn more about i-lab venture Naya Studio, check out their profile on our Facebook page or visit www.naya.studio Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

The Other Side speaker series engages innovation luminaries from across the globe to share “the other side” of their journeys: their successes – and their failures – and their perspective on what it takes to excel in today’s complex world.Uploaded 19-04-16We were ecstatic to have Stéphane Bancel, President and CEO of Moderna Therapeutics, join us as our speaker in the Other Side series. Under Bancel’s leadership, Moderna has become one of the fastest-growing companies in the biotech industry, raising more than $1.2 billion since 2011 to develop messenger RNA therapeutics. Much of Moderna’s unprecedented rate of growth while Bancel has been at the helm can be attributed to how the company has leveraged its novel platform technology, as well as its spinout ventures and partnerships with AstraZeneca, Merck and Alexion. Prior to Moderna, Bancel was the CEO of bioMérieux, a world leader in the diagnostics industry, where he was named #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.As we dove into the other side of Bancel’s journey, we learned about the various roles he’s played since graduating from Harvard business: From managing manufacturing at Eli Lilly to serving as Senior Partner at Flagship Ventures. More importantly, we discovered the underlying motivations that have contributed to his ambitious belief and vision for making Moderna one of the most successful and impactful biotech companies in the world. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices